Video

Interesting Trials in HER2+ Breast Cancer

Author(s):

Joyce O'Shaughnessy, MDSara M. Tolaney, MD, MPH

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Data from the following clinical trials are discussed:

  • LBA15 - Primary outcome of the phase 3 SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pretreated HER2-positive locally advanced or metastatic breast cancer
  • 139P - HER2+/HR+ breast cancer patients at high risk of relapse derive benefit from extended adjuvant treatment with neratinib: An exploratory analysis from ExteNET study
Related Videos
A panel of 3 experts on breast cancer
Paolo Tarantino, MD
A panel of 3 experts on breast cancer
Kevin Kalinsky, MD, MS,
Arya Mariam Roy, MBBS
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
VK Gadi, MD, PhD
Ana Christina Garrido-Castro, MD
Julia Foldi, MD, PhD
Related Content
Karthik V. Giridhar, MD
June 12th 2024

Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Erin Frances Cobain, MD
June 8th 2024

MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Shengfeng Li
June 3rd 2024

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion

Giuseppe Curigliano, MD, PhD
June 2nd 2024

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer